Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.

Background: Although glargine and detemir are both FDA-approved in the U.S. as long-acting insulin analogues, inherent differences in the insulins may lead to varying outcomes.